Funding Mishaps Rattle Review Panel

Every member of the scientific review panel at Texas’s $3-billion cancer research funding agency has quit, citing concerns about a lack of proper peer review.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Wikimedia Commons, Kuebi The Cancer Prevention Research Institute of Texas (CPRIT) is facing questions after its entire 8-member scientific review council resigned, blaming serious concerns about the integrity of the funding agency’s peer-review procedure. And it seems many of the institute’s roster of 100 expert peer reviewers, based at universities across the country, are also worried enough to quit.

CPRIT was established in 2007 to allocate up to $3 billion dollars from bond sales over 10 years for cancer research and prevention across Texas. But problems surfaced earlier this year with regard to how funding decisions are made.

This past May, Alfred Gilman, the Nobel Prize-winning biochemist who served as chief scientific officer of CPRIT, announced that he would step down this fall because the board had approved an “incubator” grant of up to $18 million to the University of Texas (UT) MD Anderson Cancer Center in Houston after a 3-week deliberation that did not involve proper scientific review. The board had also delayed grants, many destined for Gilman’s former employer, the UT Southwestern Medical Center in Dallas—a move that Gilman viewed as an ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies